Approximately 50% of acute myeloid leukemia (AML) patients do not respond to induction
therapy (primary induction failure [PIF]) or relapse after< 6 months (early relapse [ER]). We …

Multiparameter flow cytometry (MFC) is one of the essential ancillary methods in bone
marrow (BM) investigation of patients with cytopenia and suspected myelodysplastic …

Myelodysplastic syndrome (MDS) is a heterogeneous, clonal hematological disorder
characterized by ineffective hematopoiesis, cytopenia, morphologic dysplasia, and …

Myelodysplastic syndrome (MDS) is a chronic hematologic disorder that frequently evolves
to more aggressive stages and in some cases leads to acute myeloid leukemia (AML). MDS …

Myelodysplastic syndromes (MDS) comprise hematological disorders that originate from the
neoplastic transformation of hematopoietic stem cells (HSCs). However, discrimination …

The α chain of interleukin 3 receptor (IL-3Rα or CD123), together with the common β (βc)
subunit, forms a high-affinity IL-3R with biological function. In recent years, emerging …

Simple Summary CD123 is overexpressed in multiple hematologic malignancies. Advances
in CD123-targeted therapies over the past decade have positioned this molecule as an …

Highlights•Autologous T cells derived from MDS patients can be successfully transduced
and are highly active in multiple functional assays.•A xenograft model was developed in …

Chimeric antigen receptor-modified T-cells (CART) are a potent and targeted
immunotherapy which have induced remissions in some patients with chemotherapy …

In work spanning several decades, extensive studies have focused on the properties of
malignant stem cells that drive the pathogenesis of acute myeloid leukemia (AML). However …